Logo image of ETNB

89BIO INC (ETNB) Stock Overview

USA - NASDAQ:ETNB - US2825591033 - Common Stock

14.85 USD
+0.01 (+0.07%)
Last: 10/3/2025, 8:00:02 PM
14.85 USD
0 (0%)
After Hours: 10/3/2025, 8:00:02 PM

ETNB Key Statistics, Chart & Performance

Key Statistics
52 Week High15.06
52 Week Low4.16
Market Cap2.20B
Shares148.31M
Float147.46M
Yearly DividendN/A
Dividend YieldN/A
EPS(TTM)-3.61
PEN/A
Fwd PEN/A
Earnings (Next)11-05 2025-11-05/amc
IPO11-11 2019-11-11
Sector
GICS SectorHealth Care
GICS IndustryBiotechnology
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryBiotechnology


ETNB short term performance overview.The bars show the price performance of ETNB in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months 0 50 100 150

ETNB long term performance overview.The bars show the price performance of ETNB in the last 1, 2 and 3 years. 1 year 2 years 3 years 20 40 60 80 100

The current stock price of ETNB is 14.85 USD. In the past month the price increased by 67.42%. In the past year, price increased by 106.54%.

89BIO INC / ETNB Daily stock chart

ETNB Competitors/Peers

The largest stocks on the US markets in the "Biotechnology" sub-industry
Full List
Symbol
Company Name
TA
FA
PE
Market Cap
ABBV ABBVIE INC 22.09 413.22B
AMGN AMGEN INC 13.66 160.37B
GILD GILEAD SCIENCES INC 14.56 139.83B
VRTX VERTEX PHARMACEUTICALS INC 23.81 103.40B
REGN REGENERON PHARMACEUTICALS 13.15 63.59B
ALNY ALNYLAM PHARMACEUTICALS INC N/A 59.82B
ARGX ARGENX SE - ADR 86.3 48.96B
ONC BEONE MEDICINES LTD-ADR 6.01 37.77B
INSM INSMED INC N/A 33.22B
BNTX BIONTECH SE-ADR N/A 25.36B
BIIB BIOGEN INC 9.99 23.44B
NTRA NATERA INC N/A 22.97B

About ETNB

Company Profile

ETNB logo image 89bio, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of innovative therapies for the treatment of liver and cardio-metabolic diseases. The company is headquartered in San Francisco, California and currently employs 93 full-time employees. The company went IPO on 2019-11-11. The firm is focused on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. The Company’s lead product candidate, pegozafermin, a specifically engineered glycoPEGylated analog of fibroblast growth factor 21 (FGF21), is being developed for the treatment of metabolic dysfunction-associated steatohepatitis (MASH). Pegozafermin is engineered to protect against proteolysis and reduce renal clearance and optimize its potency, enabling the potential use of a lower dosage/dose. Pegozafermin has been optimally constructed with two mutations via substitutions with natural amino acids at site-specific positions (173 and 176) toward the C-terminus end of the hormone.

Company Info

89BIO INC

655 Montgomery Street, Suite 1500

San Francisco CALIFORNIA 94104 US

CEO: Rohan Palekar

Employees: 93

ETNB Company Website

ETNB Investor Relations

Phone: 14154329270

89BIO INC / ETNB FAQ

What is the stock price of 89BIO INC today?

The current stock price of ETNB is 14.85 USD. The price increased by 0.07% in the last trading session.


What is the ticker symbol for 89BIO INC stock?

The exchange symbol of 89BIO INC is ETNB and it is listed on the Nasdaq exchange.


On which exchange is ETNB stock listed?

ETNB stock is listed on the Nasdaq exchange.


What is the price forecast or stock price prediction for 89BIO INC stock?

17 analysts have analysed ETNB and the average price target is 30.79 USD. This implies a price increase of 107.31% is expected in the next year compared to the current price of 14.85. Check the 89BIO INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.


What is 89BIO INC worth?

89BIO INC (ETNB) has a market capitalization of 2.20B USD. This makes ETNB a Mid Cap stock.


How many employees does 89BIO INC have?

89BIO INC (ETNB) currently has 93 employees.


What are the support and resistance levels for 89BIO INC (ETNB) stock?

89BIO INC (ETNB) has a support level at 14.75 and a resistance level at 14.88. Check the full technical report for a detailed analysis of ETNB support and resistance levels.


Should I buy 89BIO INC (ETNB) stock?

There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:


Does 89BIO INC (ETNB) stock pay dividends?

ETNB does not pay a dividend.


When does 89BIO INC (ETNB) report earnings?

89BIO INC (ETNB) will report earnings on 2025-11-05, after the market close.


What is the Price/Earnings (PE) ratio of 89BIO INC (ETNB)?

89BIO INC (ETNB) does not have a PE ratio as the earnings reported over the last twelve months were negative (-3.61).


What is the Short Interest ratio of 89BIO INC (ETNB) stock?

The outstanding short interest for 89BIO INC (ETNB) is 10.42% of its float. Check the ownership tab for more information on the ETNB short interest.


ETNB Technical Analysis

ChartMill assigns a technical rating of 10 / 10 to ETNB. When comparing the yearly performance of all stocks, ETNB is one of the better performing stocks in the market, outperforming 94.38% of all stocks.


Chartmill TA Rating
Chartmill Setup Rating

ETNB Fundamental Analysis

ChartMill assigns a fundamental rating of 2 / 10 to ETNB. ETNB scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

ETNB Financial Highlights

Over the last trailing twelve months ETNB reported a non-GAAP Earnings per Share(EPS) of -3.61. The EPS decreased by -83.25% compared to the year before.


Industry RankSector Rank
PM (TTM) N/A
ROA -74.6%
ROE -86.29%
Debt/Equity 0.07
Chartmill High Growth Momentum
EPS Q2Q%-47.92%
Sales Q2Q%N/A
EPS 1Y (TTM)-83.25%
Revenue 1Y (TTM)N/A

ETNB Forecast & Estimates

17 analysts have analysed ETNB and the average price target is 30.79 USD. This implies a price increase of 107.31% is expected in the next year compared to the current price of 14.85.


Analysts
Analysts84.71
Price Target30.79 (107.34%)
EPS Next Y35.3%
Revenue Next YearN/A

ETNB Ownership

Ownership
Inst Owners110.73%
Ins Owners0.55%
Short Float %10.42%
Short Ratio3.48